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L I T E R A T U R E

H I G H L I G H T S
Selected abstracts and commentary

NEUROLOGY
COMMENTARY
The paper by Pandian et al is a review article related to stroke in developing countries. The literature related to this topic is limited
despite a huge burden of stroke in the developing world. Factors responsible for the extremely low use of thrombolytics in these
countries are discussed. The article not only provides insight and analysis of the situation but makes recommendations. This
article is useful for clinicians and scientists involved in stroke research.
The EXCITE study is the first randomized, multi-center trial evaluating the role of constraint therapy in stroke rehabilitation. Upper
extremity functional limitation is present in 50-70% stroke survivors and is frustrating for occupational as well as physical
therapists. That constraining the normal hand leading to forced utilization of the hemiparetic or hemiplegic hand results in
significant recovery is a promising finding. The article also discusses cortical activation and other mechanisms underlying this
recovery.
The study by Kupsch and colleagues is promising. Primary generalized and segmental dystonia is a debilitating condition usually
refractory to medical therapy and poorly responsive to botox therapy. This is the first study reporting up to 50% improvement in
these patients by deep brain stimulation of the globus pallidus interna (GPi) as compared to sham stimulation. The treatment was
associated with adverse events over the 9-month study period. Long-term effects and adverse events are not known. Despite the
cost and the side effects, the findings are promising and provide hope for these otherwise incapacitated patients.
Mohammad Wasay
Associate Professor of Neurology
Aga Khan University

International Journal of Stroke 2007 Feb; 2:17-26.
Pandian JD, Padma V, Vijaya P, Sylaja PN, Murthy JMK
Department of Neurology, Royal Brisbane and Women's Hospital, Brisbane, Australia; and Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
jeyarajpandian@yahoo.co.in

STROKE THROMBOLYSIS IN DEVELOPING COUNTRIES
Background: Over the past few decades, the burden of stroke
in developing countries has grown to epidemic proportions.
Two-thirds of global stroke occurs in low- and middle-income
countries. We have found that little information is obtainable
concerning the availability of thrombolys is the rapy in
developing countries. Summary of review: The epidemiology of
stroke is well investigated in the developed world; however, in
the developing world stroke is less well documented. Most of
the available stroke data from these countries are hospitalbased. Stroke thrombolysis is currently used in few developing
countries like Brazil, Argentina, Senegal, Iran, Pakistan, China,
Thailand, and India. The two main barriers for implementation
of thrombolysis therapy in developing countries are the high
cost of tissue plasminogen activator and lack of proper
infrastructure. Most of the centers with the infrastructure to
deliver thrombolysis for stroke are predominantly private
sector, and only available in urban areas. Conclusion: Until a
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more cost-effective thrombolytic agent and the proper
infrastructure for widespread use of thrombolysis therapy are
available, developing nations should focus on primary and
secondary stroke prevention strategies and the establishment
of stroke units whereve r possible. Such m ulti-faceted
approaches will be more cost-effective for developing countries
than the use of thrombolysis.
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Journal of the American Medical Association 2006 Nov; 296:2095-2104.
Wolf SL et al, for the EXCITE investigators
Center for Rehabilitation Medicine, Emory University, Atlanta, USA. swolf@emory.edu

EFFECT OF CONSTRAINT-INDUCED MOVEMENT THERAPY ON UPPER EXTREMITY FUNCTION
3 TO 9 MONTHS AFTER STROKE: THE EXCITE RANDOMIZED CLINICAL TRIAL
CONTEXT: Single-site studies suggest that a 2-week program of
constraint-induced movement therapy (CIMT) for patients more
than 1 year after stroke who maintain some hand and wrist
movement can improve upper extremity function that persists
for at least 1 year. OBJECTIVE: To compare the effects of a 2week multisite program of CIMT vs usual and customary care
on improvement in upper extremity function among patients
who had a first stroke within the previous 3 to 9 months.
DESIGN AND SETTING: The Extremity Constraint Induced
Therapy Evaluation (EXCITE) trial, a prospective, single-blind,
randomized, multisite clinical trial conducted at 7 US academic
institutions between January 2001 and January 2003.
PARTICIPANTS: Two hundred twenty-two individuals with
predominantly ischemic stroke. INTERVENTIONS: Participants
were assigned to receive either CIMT (n = 106; wearing a
restraining mitt on the less-affected hand while engaging in
repetitive task practice and behavioral shaping with the
hemiplegic hand) or usual and customary care (n = 116;
ran ging from no treat ment after co nc lud ing formal
reh abili ta tio n to p ha rmac olo gi c or ph ys iot her a pe utic
interventions); patients were stratified by sex, prestroke
dominant side, side of stroke, and level of paretic arm
function. MAIN OUTCOME MEASURES: The Wolf Motor
Function Test (WMFT), a measure of laboratory time and

strength-based ability and quality of movement (functional
ability), and the Motor Activity Log (MAL), a measure of how
well and how often 30 common daily activities are performed.
RESULTS: From baseline to 12 months, the CIMT group
showed greater improvements than the control group in both
the WMFT Performance Time (decrease in mean time from
19.3 seconds to 9.3 seconds [52% reduction] vs from 24.0
seconds to 17.7 seconds [26% reduction]; between-group
difference, 34% [95% confidence interval {CI}, 12%-51%];
P<.001) and in the MAL Amount of Use (on a 0-5 scale,
increase from 1.21 to 2.13 vs from 1.15 to 1.65; betweengroup difference, 0.43 [95% CI, 0.05-0.80]; P<.001) and
MAL Quality of Movement (on a 0-5 scale, increase from 1.26
to 2.23 vs 1.18 to 1.66; between-group difference, 0.48
[95% CI, 0.13-0.84]; P<.001). The CIMT group achieved a
decrease of 19.5 in self-perceived hand function difficulty
(Stroke Impact Scale hand domain) vs a decrease of 10.1 for
the control group (between-group difference, 9.42 [95% CI,
0.27-18.57]; P=.05). CONCLUSION: Among patients who had
a stroke within the previous 3 to 9 months, CIMT produced
statistically significant and clinically relevant improvements in
arm motor function that persisted for at least 1 year.Trial
Registration clinicaltrials.gov Identifier: NCT00057018.

New England Journal of Medicine 2006 Nov; 355:1978-1990.
Kupsch A et al, for the Deep Brain Stimulation for Dystonia Study Group
Charite Universitatsmedizin, Campus Virchow, Berlin, Germany. j.volkmann@neurologie.uni-kiel.de

PALLIDAL DEEP-BRAIN STIMULATION IN PRIMARY GENERALIZED OR SEGMENTAL DYSTONIA
BACKGROUND: Neurostimulation of the internal globus pallidus
has been shown to be effective in reducing symptoms of
primary dystonia. We compared this surgical treatment with
sham stimulation in a randomized, controlled clinical trial.
ME TH ODS: For ty pat ient s with pr imary s eg men tal or
generalized dystonia received an implanted device for deepbrain stimulation and were randomly assigned to receive either
neurostimulation or sham stimulation for 3 months. The
primary end point was the change from baseline to 3 months
in the severity of symptoms, according to the movement
subscore on the Burke-Fahn-Marsden Dystonia Rating Scale
(range, 0 to 120, with higher scores indicating greater
impairment). Two investigators who were unaware of treatment
sta tus ass ess ed th e s everity of dystonia by reviewing
PAKISTAN JOURN AL OF NEUROLOGICAL SCI ENCES

videotaped sessions. Subsequently, all patients received openlabel neurostimulation; blinded assessment was repeated after
6 months of active treatment. RESULTS: Three months after
randomization, the change from baseline in the mean (+/-SD)
m o ve ment s cor e was s ignif ican tly grea te r in the
neurostimulation group (-15.8+/-14.1 points) than in the
sham-stimulation group (-1.4+/-3.8 points, P<0.001). During
the open-label extension period, this improvement was
su sta i ne d amon g pa ti ents ori gi na lly assi gned to th e
neurostimulation group, and patients in the sham-stimulation
group had a similar benefit when they switched to active
treatment. The combined analysis of the entire cohort after 6
months of neurostimulation revealed substantial improvement
in all movement symptoms (except speech and swallowing),
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the level of disability, and quality of life, as compared with
baseline scores. A total of 22 adverse events occurred in 19
patients, including 4 infections at the stimulator site and 1
lead dislodgment. The most frequent adverse event was
dysarthria. CONCLUSIONS: Bilateral pallidal neurostimulation
for 3 months was more effective than sham stimulation in
patients with primary generalized or segmental dystonia.
(ClinicalTrials.gov number, NCT00142259 [ClinicalTrials.gov].)
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